Innovative Partnership Enhances CBD IV Therapy Approach

Innovative Partnership Enhances CBD IV Therapy
PICO IV, known for introducing the world's first sterile CBD emulsion, has formed a strategic partnership with Liquivida, a leader in IV therapy and wellness solutions. This collaboration aims to push the boundaries of IV hydration while ensuring top-tier safety and educational standards. As health and wellness innovations continue to expand, this partnership marks a significant leap forward for both entities.
Sam Tejada Joins as Spokesperson
In a notable development, Liquivida's founder, Sam Tejada, who is also the Chairman of the Leadership Advisory Board for the American IV Association (AIVA), has been appointed to the PICO IV Advisory Board. Tejada’s role as a spokesperson is crucial, as he will advocate for the medicinal capabilities of CBD and inform the public about the endocannabinoid system (ECS), a vital regulatory network that supports overall health.
Insights from Sam Tejada
"This isn't just a new product, it's the beginning of a new category of treatment," Tejada stated passionately. He highlighted, "At Liquivida, we're very selective about what we incorporate into our clinics, and PICO IV exemplifies the highest standards of safety, scientific backing, and purpose. We are thrilled about the implications this holds for the future of IV therapy and patient health."
The Advancement of CBD Technology
Selecting effective methods of delivering CBD has gained momentum, particularly since legislative changes in recent years. However, traditional oral and topical applications can fall short, as only a fraction of CBD is effectively absorbed. Through its innovative technology, PICO IV has transformed CBD into finer particles, referred to as 'pico', enhancing absorption rates and bioavailability to nearly 100%. This groundbreaking approach allows for more precise dosing and quick systemic effects, vital for both clinical environments and performance-oriented applications.
Commitment to Safety and Purity
PICO IV stands out as the first and only company to offer CBD in a sterile solution format. Their products are manufactured in a cGMP facility and are subject to rigorous testing. Utilizing e-beam sterilization ensures a contamination-free product, without compromising its quality. Joe Young, the Chief Executive Officer at PICO IV, said, "We are keenly aware of the responsibilities that come with introducing sterile CBD to the market. Safety is our utmost priority, and we have taken meticulous measures throughout our manufacturing process to ensure every product is trustworthy."
Education on the Endocannabinoid System
A fundamental aim of this partnership is to foster greater understanding of the ECS among healthcare providers. This system, while essential for overall health maintenance, is often overlooked in conventional medical training. Liquivida is committed to enabling education among its affiliate doctors and their patients regarding the ECS, adding to the growing body of knowledge around sterile CBD and its integration into clinical practices.
As the sciences surrounding CBD and IV therapy evolve, Liquivida will play a pivotal role in equipping its nationwide network of healthcare professionals with knowledge about this system and the potential benefits of PICO IV. This shared mission ensures that accessible and scientifically grounded wellness solutions are available to a broader audience.
Both PICO IV and Liquivida are stepping into a transformative period, characterized by increasing interest in advanced wellness options. As practitioners look for evidence-based solutions that amalgamate natural healing with clinical integrity, this partnership will undoubtedly pave the way for a more thorough understanding of and access to these therapies.
About PICO IV
PICO IV specializes in the development of the world's first sterile CBD solution, which adheres to FDA-approved filtration standards. Their flagship formula delivers cannabinoids with unparalleled purity and precision.
About Liquivida
Liquivida is a prominent wellness franchise that combines scientific principles with self-care approaches, offering a range of services including IV therapy, weight loss programs, hormone health, and regenerative therapies, all designed to empower individuals to lead healthier lifestyles.
Frequently Asked Questions
What is the significance of PICO IV's partnership with Liquivida?
The partnership aims to advance IV hydration methods while educating both providers and patients on the benefits of sterile CBD.
Who is Sam Tejada and what role does he play?
Sam Tejada is the founder of Liquivida, appointed as a spokesperson for PICO IV to raise awareness about CBD's clinical potential.
How does PICO IV's technology enhance CBD absorption?
PICO IV's technology reduces CBD particle size, allowing for nearly 100% bioavailability and more efficient absorption through IV delivery.
What facilities are involved in PICO IV's manufacturing process?
PICO IV produces its sterile CBD solution in a cGMP facility, ensuring rigorous quality and safety standards are met.
Why is education on the endocannabinoid system important?
Understanding the ECS is essential for health providers to effectively integrate CBD therapies into clinical practices, enhancing patient care.
About The Author
Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.